How to prevent hair loss on GLP-1
You are dealing with a symptom and want to know if it is expected.
Reference and calculator, not medical advice. This page explains how something works; it does not tell you what to take. Last reviewed August 2026.
No prevention strategy is established in any of the labelling. What the labels do provide is a variable that clearly tracks with the reaction — dose — and an explicit statement of what the manufacturers think it travels with.
The clearest number in any of the labels
Wegovy trials, women only, same measurement across three arms. Rate rises with dose while the label attributes the effect to weight reduction rather than to the drug.
Men in the same trials: 0% · 0% · 0.2%. The sex difference is larger than the dose difference, which is the part almost no summary of this topic mentions.
Why the women’s figure for 2.4 mg differs from the table above: these three arms come from the 7.2 mg trial programme, while the other figure is pooled from three earlier weight-management trials. Both are in the label and both report 3.3% overall at 2.4 mg — the sex split differs because the trial populations do. Both are shown rather than picking the more striking one.
Reported rates rise from 1.0% on placebo to 3.3% at Wegovy 2.4 mg to 5.8% at 7.2 mg. Both labels attribute the reactions to weight reduction. Put together, the implication people reach for is that losing weight more slowly might reduce it — which is a reasonable inference and still an inference, not a finding. No trial tested slower titration against hair loss as an outcome.
It also runs directly against the reason for taking the medication. Titration schedules exist to manage gastrointestinal tolerability and reach an effective dose; rewriting one to protect your hair is a trade with real costs on the other side, and it is a prescriber's decision rather than a self-directed experiment.
What each label actually reports
Incidence figures come from the adverse-reaction sections of the prescribing information. The two weight-management products report trial data; the diabetes products list alopecia only as a postmarketing report.
| Product | Reported in | Women | Men |
|---|---|---|---|
| Wegovy Semaglutide | Clinical trials | 4% | 0.9% |
| Zepbound Tirzepatide | Clinical trials | 7.1% | 0.5% |
| Ozempic Semaglutide | Postmarketing reports only | no denominator | no denominator |
| Mounjaro Tirzepatide | Postmarketing reports only | no denominator | no denominator |
| Rybelsus Semaglutide (oral) | Postmarketing reports only | no denominator | no denominator |
| Saxenda Liraglutide | Postmarketing reports only | no denominator | no denominator |
| Trulicity Dulaglutide | Postmarketing reports only | no denominator | no denominator |
A postmarketing entry means the reaction has been reported after approval but the label gives no rate, because spontaneous reports have no denominator. It is not evidence that the rate is lower — only that it was not measured. Every figure above is checked against the label linked at the foot of this page.
Common questions
- Is holding at a lower step a recognised approach?
- Holding a step is routine practice for tolerability generally and plenty of people maintain below the labelled maximum. Doing it specifically for hair is not something the labels address, and the decision belongs with your prescriber.
- Does starting protein early help?
- Adequate protein matters on a sharply reduced appetite for lean-mass reasons that are worth taking seriously on their own. Whether it prevents this particular reaction is not established in these documents.
- Can I do anything before it starts?
- Knowing your baseline is the one genuinely useful thing. If thyroid and iron status are checked before or early in treatment, you are not trying to reconstruct that picture later while worried.
Sources and last review
This page is general reference rather than a dosing table, so it quotes no figures from a label. Nothing here is reviewed by a clinician, and this site does not employ one — which is exactly why what I do publish stays traceable to its source.
- This page carries no product-specific dosing figures. The labels behind everything on this site are listed on the sources page, and the originals live on DailyMed.
Transcribed from the labels above and checked by me — Gavin, who builds this site, takes a GLP-1, and is not a clinician. Last reviewed August 2026. Found an error? [email protected] — I treat corrections as bugs. How this site is built and funded.
Also searched as: how to prevent hair loss on glp-1
Related
- GLP-1 hair lossSide effects
- Do GLP-1 cause hair lossSide effects
- GLP-1 hair loss treatmentSide effects
- How to stop hair loss from GLP-1 femaleSide effects
- GLP-1 hair loss supplementSide effects
- How to stop hair loss from GLP-1Side effects
- GLP-1 side effects hair lossSide effects
- How to stop GLP-1 hair lossSide effects